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Abstract: Of the millions of HTLV-1 infected carriers worldwide, 3–5% will develop an 
aggressive T-cell neoplasm that is highly refractory to conventional therapy. The virus 
carries the Tax oncogene which constitutively activates the NFκB pathway. This co-option 
of signaling through NFκB provides for the HTLV-1 infected cell an escape from cell cycle 
arrest and apoptosis, a steady source of growth factors, and a mechanism by which the 
virus can activate its own target cell. Therapies that target the NFκB pathway sensitize 
adult T-cell leukemia/lymphoma (ATLL) cells to apoptosis. A focus on translational 
interrogation of NFκB inhibitors in animal models and ATLL patients is needed to advance 
NFκB-targeted ATLL therapies to the bedside.  
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1. Introduction 
Of the 15–20 million HTLV-1 infected carriers worldwide, more than 500,000 will develop an 
aggressive T-cell neoplasm that is highly refractory to conventional therapy. Despite intensive efforts 
to improve the overall survival, adult T-cell leukemia/lymphoma (ATLL) remains one of the 
hematologic malignancies with the poorest prognosis. ATLL is typically preceded by decades of 
clinical latency during which infected cells accumulate selectable traits leading to malignant 
transformation. Host pathways commandeered by the virus can be used as therapeutic targets and a 
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constitutively activated NFκB pathway has emerged as an essential hit in the development of ATLL. 
Research into the mechanisms underlying HTLV-1 modulation of the NFκB pathway has revealed the 
extent to which HTLV-1 oncogenesis is dependent on the NFκB pathway [1,2]. Mouse models of 
ATLL have also been created to recapitulate the virus induced, NFκB-dependent leukemias and 
lymphomas. Translational investigations of NFκB inhibitors in mouse models and ATLL patients are 
necessary to bring this work from bench to bedside.  
2. HTLV-1 Oncogenesis Depends on NFκB 
During decades of clinical latency HTLV-1 modulates host signaling pathways to promote 
proliferation of infected cells. Among the genes carried in the viral genome, the 40 kDa viral 
transcriptional transactivator (Tax) is sufficient to promote cellular transformation. The mechanism 
utilized by Tax to promote cellular transformation is multi-faceted, broadly involving activation of 
proliferation, dysregulation of cell cycle checkpoints, and promotion of genetic instability. While the 
affects of Tax expression in a cell are diverse, Tax depends on a central signaling pathway for its 
transforming activity. Mouse models in which Tax is expressed in the lymphocyte compartment have 
constitutively active NFκB and reproduce many aspects of HTLV-1 pathogenesis (Table 1). Tax 
expression in the absence of other viral factors is sufficient to activate the NFκB pathway and cause 
leukemia, lymphoma, solid tumors, splenomegaly, and osteolytic disease. More than 20 years ago 
Nerenberg identified a role for NFκB in tumor growth in a transgenic mouse model in which Tax, 
under the regulation of the HTLV-1 LTR, developed neurofibromas [3]. However, LTR-driven Tax 
expression in mouse models most often resulted in disorders associated with chronic inflammation, 
another NFκB-mediated process [4–7]. Other promoters were used in transgenic constructs to restrict 
Tax expression to the lymphoid compartment and better model ATLL-like malignancies. In one mouse 
model, the granzyme B promoter was used to drive Tax expression in activated T-cells and NK cells. 
These mice developed leukemia and lymphoma and tumors associated with high levels of NFκB and 
NFκB-regulated genes [8]. Tax driven by the Lck promoter also causes an ATLL-like malignancy in 
transgenic mice in which NFκB is constitutively elevated [9,10]. The necessity of NFκB in  
Tax-mediated transformation was confirmed using HTLV-1 molecular clones in which a single point 
mutation in the Tax oncogene that disrupts its ability to activate the NFκB pathway (Figure 1) also 
eliminates the virus’ ability to transform primary cells [11,12]. These data establish that constitutive 
activation of the NFκB pathway is essential in the process of Tax-mediated oncogenesis.  
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Table 1. Summary of tax transgenic mouse models of adult T-cell leukemia/lymphoma (ATLL). 
Promoter Gene Strain Diseases Observed 
Relevance to 
ATLL 
Merits of Model 
Weaknesses of 
Model 
Therapies 
Tested 
Ref 
HTLV LTR 
Tax 
C57BL/
6 
X 
DBA/2 
X 
CD1 
Mesenchymal 
Tumors Thymic 
atrophy 
Not Observed 
Overexpression of 
TGF-beta, activation of 
NFκB 
Tax transforms 
fibroblasts but not 
thymocytes 
NFκB 
ODN 
[49] 
[50] 
[51] 
Neurofibromatosis 
Adrenal Tumors 
Not Observed 
Tax activation of 
Nerve growth factor 
and repression of NF1 
Not associated with 
HTLV associated 
diseases in humans 
None 
[52] 
[53] 
[54] 
[55] 
Muscle degeneration Myositis 
High levels of Tax 
expression in muscle 
Incomplete 
penetrance 
None [56] 
Exocrinopathy 
Lymphadenopathy 
Splenomegaly 
Sjogren 
syndrome 
ocular lesions 
NfκB inflammatory 
disorders associated 
with Tax 
Caused by B not T 
lymphocytes 
None 
[57] 
[58] 
Bone Turnover 
Lytic bone 
lesions 
NFkB associated bone 
lesions 
Incomplete 
penetrance 
None [59] 
Tax βgal 
Mesenchymal 
Tumors 
Not Observed 
Tax expression in 
response to tissue 
damage 
Tissue damage not 
correlated with 
tumor 
None 
[60] 
[61] 
HTLV LTR 
pX 
C57BL/
6 X 
CD1 
Thymic Atrophy Not Observed 
Effects of pX on 
thymus independent of 
promoter used 
pX gene expression 
not detectable 
None [62] 
Ig-SV40 
MMTV 
LTR 
HTLV LTR 
pX 
C3H/ 
HeN 
Inflammatory 
Arthropathy 
Osteogenesis 
Autoimmunity 
Arthritis 
IL-1, IL-6, TNFα, 
TGFβ detected in 
joints.  
No malignancy 
Anti-Fas 
mAb  
(RK-8) 
[4] 
[5] 
[7] 
[63] 
[64] 
Tax 
CD4 Tax 
HTLV LTR Tax C3H 
Mesenchymal 
Tumors 
NFκB 
mediated 
malignancy 
IκB degradation leads 
to constitutive NFκB 
activation  
Expression 
restricted to CNS 
and testes 
None [65] 
Ig Tax 
FVB/N 
Not Observed Not Observed 
Lymphoma with CNS 
involvement 
Roles of c-Myc and 
Tax unclear  
None [66] Ig 
HTLV LTR 
Tax  
c-myc 
CD4+ Lymphoma 
CNS Tumors 
CD4+ 
Lymphoma 
GzmB 
Tax 
C57BL/
6 
LGL lymphoma 
Leukemia 
Osteolytic lesions 
Splenomegaly 
Lymphadenopathy 
Hypercalcemia Lymphoma 
Leukemia 
Lytic bone 
lesions 
Hypercalcemia 
NFkB mediated 
leukemia lymphoma 
Not a CD4+ T cell 
malignancy 
Bortezomi
b 
[8] 
[36] 
Tax  
IL-2−/− 
IL-2 not required for 
phenotype 
Not a CD4+ T cell 
malignancy 
None [29] 
Tax  
IFNγ−/− 
Accelerated tumor 
onset and death 
May also affect 
tumor immunity 
None [32] 
Tax 
P53−/− 
Accelerated disease 
progression 
Only seen in 
P53+/− mice 
None [22] 
GzmB 
ApoE 
Tax 
OPG 
Reduced cancer and 
bone lesions 
Causes 
osteopetrosis 
Zoledronic 
Acid 
[27] 
GzmB 
HTLV LTR 
Tax 
LUC 
C57BL/
6 
X 
FVB 
Bioluminescent tumors 
Not a CD4+ T cell 
malignancy 
None [31] 
GzmB 
HTLV LTR 
Tax  
LUC 
ARF−/− 
Lymphoma 
Bone Turnover 
Osteosarcoma 
ARF−/− is not 
equivalent to p53−/− 
Osteosarcoma not 
associated with 
ATLL 
Zoledronic  
Acid 
[67] 
GzmB 
HTLV LTR 
TCR 
Tax 
LUC 
TCRova 
C57BL/
6 
X 
FVB 
X 
BALB/c 
Leukemia 
Lymphoma 
Lymphadenopathy 
Tax induced by 
wounding and T cell 
activation leads to 
enhanced 
tumorigenesis 
Primary malignancy 
not a not a CD4+ T 
cell malignancy 
None [35] 
EμSRα 
TET 
TET 
tTA 
Tax 
M47 
FVB/N 
Alopecia 
Hyperkeratosis 
Splenomegaly 
Skin Lesions 
Tet-inducible model 
allows repression of 
Tax  
No malignancy None [68] 
EμSRα 
TET 
tTA 
M22 
Not observed Not Observed 
Control establishes 
role of NFκB in 
disease 
Lck-prox Tax 
C57BL/
6 
CD4- CD25+ pre-T 
cell Leukemia 
Lymphoma 
Leukemia 
Lymphoma 
Cancer stem cells 
derived from these 
mice recapitulate 
disease in SCID 
Not a CD4+ T cell 
malignancy 
As2O3 + 
IFN-α 
AMD3100 
[9] 
[69] 
[70] 
[71] 
Lck-dis Tax 
C57BL/
6 
X 
DBA/2 
CD4+ CD25- mature 
T cell leukemia 
lymphoma 
Arthritis 
Leukemia 
Lymphoma 
Mature CD4+ or CD8+ 
T cell malignancy 
Cells lack CD25 None 
[72] 
[73] 
CD3-ε Tax 
C57BL/
6 
X 
CBA 
Mesencymal tumors 
Mammary Adenoma 
Not Observed 
Tax associated with 
apoptosis and p53 
Not a CD4+ T cell 
malignancy 
None [74] 
Viruses 2011, 3              
 
 
889 
Figure 1. Tax activation of NFκB is required for immortalization. The creation of a 
molecular clone of HTLV-1 by Kimata et al. [11] enabled the analysis of Tax mutants for 
immortalization determinants [12]. Mutations that inhibit Tax activation of the NFκB 
pathway prevented immortalization of peripheral blood mononuclear cells (PBMC), 
whereas mutations that inhibit Tax activation of the CREB pathway allowed NFκB 
activation and Tax-mediated immortalization. 
 
3. The NFκB Signaling Pathway 
The NFκB family of transcription activators are involved in many biological processes including 
cell survival, stress responses, and development [13]. NFκB is also a central regulator of immune 
effectors including cytokine and chemokine secretion, receptor expression, antigen presentation, 
cellular proliferation, and programmed cell death. The NFκB family contains five members (RelA, 
RelB, cRel, p50, and p52) that can form 15 different homo or heterodimers with a variety of activities 
and tissue specificities. Latent or unstimulated cells retain NFκB proteins in the cytoplasm bound to 
various inhibitors of kappa B (IκB) proteins. Upon activation, IκB kinases (IKKs) release NFκB 
complexes which then translocate to the nucleus through two distinct pathways, termed canonical and 
non-canonical. These arms are distinct but retain extensive mechanisms of cross-regulation [13]. The 
canonical pathway, which is activated by pro-inflammatory signals, is IKKγ dependent, while the  
non-canonical pathway functions independent of IKKγ, instead depending on NFκB inducing kinase 
(NIK). The non-canonical pathway is activated in response to tumor necrosis factor (TNF) receptors 
during lymphoid development. It is because NFκB proteins regulate these myriad pathways that 
cancers and viral pathogens exploit NFκB to enhance proliferation, cell survival, and evasion of 
immune responses (Figure 2). Consequently, this array of human cancers could also all be targeted by 
NFκB directed therapies.  
4. Tax Targets the NFκB Pathway 
Lymphoma is commonly associated with constitutive NFκB activity and oncogenic human viruses, 
including Epstein-Barr virus (EBV), Human papillomavirus (HPV), Hepatitis B virus (HBV), and 
Hepatitis C virus (HCV) all carry viral factors that directly target and co-opt the NFκB pathway during 
gag pol env pXLTR LTR
TAX
M22
M47
ImmortalizationPBMC
HTLV-1 
Molecular 
Clone
NFkB
NFkB
CREB
CREB
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oncogenesis. HTLV-1 uses Tax in multiple strategies to efficiently activate both the canonical and 
non-canonical NFκB pathways (Figure 2).  
Figure 2. Tax targets the NFκB pathway. A simplified schematic of NFκB signaling 
pathways highlighting regulatory proteins commonly targeted by viruses [1,2,13].  
HTLV-1 Tax targets the pathway at several points. (a) Tax leads to the activation of  
receptor-associated kinases that signal through the NFκB pathway [16,17]. (b) Tax directly 
binds to IKKγ (NEMO) which leads to constitutive phosphorylation and degradation of the 
NFκB repressor IκB [15]. (c) Tax activates and recruits IKKα to p100 stimulating 
phosphorylation, ubiquitination, and processing to p52 leading to nuclear translocation [19]. 
(d) Tax alters binding or recognition of a variety of transcription factors and DNA binding 
proteins increasing the number of genes regulated by the NFκB pathway [18]. 
 
 
Tax directly interacts with several NFκB members, including RelA, p50, p52, IKKγ, and the NFκB 
precursor protein p100 such that both arms of the NFκB pathway are involved in tumorigenesis [1,14]. 
Rapid and reversible, the canonical pathway of NFκB is transient and strictly regulated. Tax activates 
the canonical pathway through a variety of mechanisms including binding to IKKγ, activating the Akt 
pathway which signals through IKKα, or by promoting phosphorylaton of p65 via activation of  
pro-inflammatory cytokines [15–18]. HTLV-1 uses the canonical pathway, through Bcl-xl, to prevent 
intrinsic apoptosis [20]. The non-canonical arm of NFκB, which involves new protein synthesis of 
p100 and RelB downstream of NIK, is slower and irreversible. Tax-induced p100 processing or its 
physical interaction with Tax in the nucleus contribute to Tax activation of the non-canonical NFκB 
pathway as well. The non-canonical pathway has a broader anti-apoptotic effect on both apoptotic 
pathways through BCL-XL, FLIP, XIAP, and CIAP, making it a more powerful therapeutic  
β
Y
α
p p
IkB
p50
RelA
p100
RelB
p50
RelA
p52
RelB
nucleus
cytoplasm
HBV e Ag
HPV E5
HIV Env
HTLV Taxa
HTLV Taxb
HCV core
EBV LMP-1
HCV NS1
HTLV Taxc
HBVx Ag
HTLV Taxd
SV40 small T
HPV E6
Receptor
complex
IKK 
complex
Canonical Non-Canonical
Cytoplasmic
NFkB
complex
Nuclear
NFkB
complex
B cell Receptor
T cell receptor
Toll-like Receptors
Growth factor Receptors
Lymphotoxin β Receptor
Virus Target
Viruses that cause inflammation-associated cancers 
target the NFκB pathway
a: Tax leads to the activation of receptor associated kinases that signal through the NFκB 
pathway.
b: Tax directly binds to IKKγ (NEMO) which leads to constitutive phosphorylation and 
degradation of the NFκB repressor IκB.  
c: Tax activates and recruits IKKα to p100 stimulating phosphorylation, ubiquitination, and 
processing to p52 leading to nuclear translocation. 
d: Tax alters binding or recognition of a v riety of transcription factors and DNA binding 
proteins increasing the number of genes regulated by the NFκB pathway   
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target [20]. In fact, the difference in transforming potential between HTLV-1 and HTLV-2 has been 
linked to the ability of HTLV-1 Tax to activate the non-canonical arm of the NFκB pathway [21]. 
5. NFκB and Apoptosis 
Constitutive activation of NFκB family members and downstream effectors provides several 
selective advantages to malignant cells. One selective advantage offered by unregulated NFκB 
signaling is the ability to bypass checkpoint controls and p53-mediated apoptosis. In transformed cell 
lines as well as freshly isolated ATLL samples, NFκB activation supports the survival and proliferation 
of HTLV-1 infected cells. Moreover, lymphoma cell lines with constitutively activated NFκB are 
resistant to a variety of inducers of apoptosis including gamma-irradiation, etoposide, and 
combinations of cycloheximide and TNF or TRAIL, and resist the activation of both the intrinsic and 
extrinsic apoptotic pathways [20]. Like ATLL cells, malignant cells arising in mouse models are also 
resistant to chemotherapy and radiation-induced apoptosis [22]. Although mutations deleting or 
inactivating p53 are common in ATLL, Tax is capable of bypassing p53-dependent cell-cycle 
checkpoints through constitutive activation of the NFκB pathway [22]. Tax is known to suppress  
a wide range of pro-apoptotic factors and stimulate expression of factors acting as apoptosis  
inhibitors [14]. The necessity of NFκB in Tax-mediated resistance to apoptosis is revealed when 
overexpression of IκB or loss of p65 represses the NFκB pathway, and re-sensitizes Tax-transformed 
cells to inducers of p53-mediated apoptosis [23]. 
6. NFκB and Inflammation 
HTLV-1 in humans is also associated with chronic inflammation which is mediated by NFκB. 
Chronic inflammation resulting from Tax-mediated canonical NFκB activity leads to HAM/TSP in 
some HTLV-1 carriers [24], but may also contribute to development of ATLL. Chronic inflammation 
promotes cancer through complex mechanisms involving cytokine mediated proliferation, stromal 
activation, immune modulation, and release of DNA damage promoting agents [25,26]. Genes 
activated by Tax in transgenic mice are directly or indirectly regulated by NFκB inducible cytokines 
that promote inflammation and immune cell infiltration (Figure 3). Tax tumor cells express IL-6,  
M-CSF, IL-1, TNF-α, and Tax expression enhances IL-6 and TNF-α expression in vitro and in vivo 
[27,28]. Moreover, malignant cells express NFκB inducible cytokines and stimulate cytokine 
production in tumor infiltrating cells and stroma. Factors produced by Tax-tumor cells cause 
splenomegaly, neutrophilia, elevated white count and anemia in transgenic mice and SCID recipients 
of tumor allografts [27,29]. Preceding tumorigenesis in transgenic mice, Tax and the NFκB pathway 
promote a state of chronic inflammation in which Tax-induced malignancies can thrive [30].  
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Figure 3. Tax transgenic mice model ATLL. Several Tax transgenic mouse models of 
ATLL have demonstrated the sufficiency of Tax as an independent oncogene. Second 
generation strains, such as the one depicted, have added capabilities, which enable  
non-invasive interrogation of various Tax activities using bioluminescence imaging 
[30,31,35].  
 
 
This inflammation-associated malignancy is Tax-dependent and promoter-dependent since SV40 
large T under the same promoter does not reproduce the inflammation promoting nature of Tax  
tumors [29,31]. Interestingly, chronic inflammation is a complicating factor because it carries both  
tumor-promoting and tumor-repressing effects. IFNγ, an NFκB inducible gene found in chronic 
inflammation, causes inhibition of tumor angiogenesis and represses tumor growth [32]. The 
mechanism by which Tax promotes inflammation and tumorigenesis is coupled by its regulation of the 
NFκB pathway.  
TAX-LUC
Leukemia
Lymphoma Osteolytic Lesions Activation of NFκB
Dynamic Tax Activity 
Non-invasive Imaging of Tax-Induced Tumors
GzmB-Tax Cell linesInflammation
Luminol-BLI
TAXGzmB LUCLTR
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7. NFκB and T-Cells 
HTLV-1 infects and transforms CD4
+
 T-cells. The NFκB pathway is essential for T-cell functions 
including T-cell development, activation, gene expression, cell cycle progression, survival, cytokine 
production, and apoptosis [13]. While Tax activates NFκB in T-cells, most freshly isolated ATLL cells 
do not express detectable levels of Tax [33]. This has been explained by the discovery that Tax is a 
primary target of cytotoxic T lymphocyte (CTL) attack, and HTLV-1 infected T-cells that express high 
levels of Tax are destroyed [34]. Is ATLL Tax-independent at the time of clinical presentation? A 
mouse model in which Tax drives expression of firefly-luciferase, allowed non-invasive, real-time 
detection of Tax activity using bioluminescence imaging (Figure 3). This model revealed that Tax 
activity, which was normally undetectable, was occasionally punctuated by short bursts of intense 
expression. Moreover, these stochastic bursts of Tax expression preceded advancing stages of 
tumorigenesis [31]. In addition, a triple-transgenic mouse strain carrying an ovalbumin-inducible  
T-cell receptor (TCR) transgene demonstrated that systemic T-cell activation accelerated the 
development of Tax-induced lymphoma [35]. Determining whether ATLL ever attains Tax 
independence awaits an inducible-Tax mouse in which Tax expression can be repressed late in 
malignancy. Importantly, in ATLL cells the NFκB pathway remains activated when Tax expression is 
repressed. Thus NFκB remains a therapeutic target even when Tax is not expressed. 
8. Targeting NFκB in vivo  
NFκB regulates the expression of a wide variety of genes implicated in proliferation, angiogenesis, 
invasion, and metastasis and the dependence of HTLV-1 oncogenesis on the NFκB pathway makes it 
an ideal target for therapeutic attack. Repression of the NFκB pathway could make ATLL cells 
sensitive to apoptosis, slow their proliferation, or repress aspects of the immune response that promote 
malignancy. In tissue culture and mouse models, non-specific inhibitors of the NFκB pathway like 
sodium salicylate or cyclopentenone prostaglandins can increase the sensitivity of Tax-tumor cells to 
apoptosis and repress NFκB-inducible cytokines IL-6, IL-10, IL-15, and IFN-γ [28]. Bortezomib is 
another non-specific inhibitor of the NFκB pathway that is capable of inhibiting proliferation of Tax 
tumors cells ex vivo and sensitizing cells to apoptosis [36]. Bortezomib treatment slowed tumor growth 
in an allograft model by increasing apoptosis, but toxicity constraints limited the efficacy of the 
treatment [36]. Bay11-7082, an IKK inhibitor, inhibits the NFκB pathway in ATLL cells and sensitizes 
HTLV-1 infected cells lines as well as primary ATLL cells to apoptosis [37]. Over the past six years 
several additional studies have therapeutically targeted the NFκB pathway in order to kill ATLL  
cells [38]. Oridonin, NIK-333, curcumin, fucoidan, histone-deacetylase inhibitors, and a derivative of 
epoxyquinomicin C have all been reported to induce apoptosis in ATLL cells by repressing the NFκB 
pathway [39–44]. These findings serve as sufficient proof of principle that NFκB-targeted therapies 
show great promise against ATLL. The field now awaits successful clinical trials in vivo. 
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9. Targeting NFκB in ATLL Patients 
The majority of ATLL patients present with acute or lymphomatous ATLL, which results in a 
median survival of 0.5–2.0 years, despite intensive chemotherapy treatment [45,46]. To determine if 
NFκB blockade is tolerated in these patients, and whether or not it improves response rates and overall 
survival, our current multicenter trial combines infusional chemotherapy (EPOCH) with bortezomib 
(Figure 4). In addition, this clinical trial includes treatment with integrase inhibitor raltegravir, which 
was found to inhibit HTLV-1 integration in tissue culture [47]. The addition of an antiviral agent to 
this ATLL treatment regimen is based on our previous clinical trial in which chemotherapy was found 
to markedly enhance virus expression in a subset of patients [48].  
Figure 4. Schema for an ATLL clinical trial using NFκB targeted therapy. The clinical  
trial shown has been approved and is currently accepting patients. Clinical trials of  
NFκB-targeted combination chemotherapies are now beginning to apply the information 
obtained from primary research to clinical practice.  
 
10. Conclusions 
Host pathways can be used as chemotherapeutic targets when they confer an essential trait to the 
cancer cell. A constitutively activated NFκB pathway represents such a target in the case of HTLV-1 
mediated ATLL. The NFκB pathway provides an escape from cell cycle arrest and apoptosis, a steady 
source of growth factors, and a mechanism by which the virus can activate its own target cell. 
Accumulating evidence supports the concept that NFκB targeted therapies sensitize ATLL cells to 
apoptosis. Research in ATLL therapies should now focus on translational interrogation of NFκB 
inhibitors in animal models and ATLL patients.  
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